Observational studyTechniques in coloproctology2026
Impact of sentinel pile on botulinum toxin treatment of chronic anal fissure: A comparative study.
Observational study in Techniques in coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of this study was to investigate if the presence of a prominent sentinel pile (SP) had any impact on the treatment success of botulinum toxin (BT) injection, as well as the clinical presentation of patients with chronic anal fissure (CAF).
methodsPatients with CAF with or without prominent sentinel piles underwent BT injection. In addition to objective healing, a detailed symptom severity score (REALISE) immediately before and 6 months after BT injection was recorded. This was a retrospective, single-center observational cohort study including consecutive patients treated in a specialized proctology unit.
resultsOf the 249 patients, 68 presented with prominent SP (27.3%). The overall objective healing rate among all patients who received a single injection of BT was found to be 74.7% at 2 months. When stratified, age distribution was similar between patients with (SP+) and without SP (SP-) (p = 0.545). However, SP was more prevalent in female patients (p = 0.009). The objective healing rates after a single BT injection were 80.7% in the SP- group and 58.8% in the SP+ group (p = 0.001). Pre-treatment REALISE scores were significantly reduced in both groups after BT injection (p < 0.001 for both). However, post-treatment scores were higher in the SP+ group compared with the SP- group (p < 0.001). Multivariable analysis confirmed SP presence as an independent predictor of reduced objective healing after BT injection.
conclusionsEven with the SP, a considerable proportion of patients with CAF heal after BT treatment and their symptoms are generally relieved. However, symptomatic improvement is less marked and the objective healing rates are lower in the SP+ group. The presence of SP may, therefore, negatively influence the clinical effectiveness of BT treatment of CAF. These findings should be interpreted in light of the retrospective single-center design and the potential for selection and recall bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.